Skip to main content

Table 2 Hazard Ratios for HF According to MAFLD Status and its subgroups

From: Metabolic Dysfunction-associated fatty liver disease and incident heart failure risk: the Kailuan cohort study

 

Case/Participants

Incidence (/1, 000 person years)

HR (95%CI)

Model 1

Model 2

Model 3

Total

     

Non-MAFLD

1945/67,930

2.19(2.09,2.28)

reference

reference

reference

MAFLD

1315/30,755

3.29(3.12,3.47)

1.51(1.40,1.62)

1.52(1.42,1.63)

1.40(1.30,1.50)

Group by the degree of fatty liver

     

Non-MAFLD

1945/67,930

2.19(2.09,2.28)

reference

reference

reference

Mild MAFLD

809/20,035

3.10(2.90,3.32)

1.41(1.30,1.53)

1.43(1.31,1.55)

1.33(1.23,1.45)

Moderate MAFLD

412/8775

3.62(3.29,3.99)

1.66(1.50,1.85)

1.68(1.50,1.86)

1.51(1.35,1.68)

Severe MAFLD

94/1945

3.77(3.08,4.61)

1.82(1.50,2.24)

1.85(1.50,2.27)

1.57(1.28,1.94)

Group by type of metabolic disorder

     

Non-MAFLD

1945/67,930

2.19(2.09,2.28)

reference

reference

reference

MAFLD1*

895/24,590

2.77(2.59,2.96)

1.31(1.21,1.42)

1.33(1.22,1.43)

1.27(1.17,1.38)

MAFLD2*

37/1107

2.64(1.91,3.64)

1.09(0.79,1.51)

1.10(0.79,1.52)

1.12(0.81,1.55)

MAFLD3*

383/5058

6.14(5.56,6.79)

2.42(2.17,2.70)

2.43(2.18,2.71)

1.95(1.73,2.20)

  1. *MAFLD1: BMI ≥ 23 kg/m2 without diabetes
  2. MAFLD2: BMI < 23 kg/m2 with at least two metabolic abnormalities but not diabetes
  3. MAFLD3: type 2 diabetes mellitus
  4. Model 1: adjusted for age, gender;
  5. Model 2: adjusted for all the variables in model 1 and Smoking, Drinking, Education level, Salt status and Physical activity;
  6. Model 3: adjusted for all the variables in model 2 and Antihypertensive treatment, Antidiabetic treatment and Lipid-lowering treatment
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us